bioAffinity Technologies
BIAF
6 hedge funds and large institutions have $193K invested in bioAffinity Technologies in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
45% more capital invested
Capital invested by funds: $134K → $193K (+$59.9K)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$84.2K |
| 2 |
Two Sigma Investments
New York
|
+$51.3K |
| 3 |
State Street
Boston,
Massachusetts
|
+$34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Financial Engines Advisors
Santa Clara,
California
|
-$104K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.04K |
| 3 |
Morgan Stanley
New York
|
-$5 |
BIAF Hedge Fund Activity: Q1 2023 in Review
6 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q1 2023, worth a combined $193K — up 45% from $134K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIAF positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $84.2K. The largest seller was Financial Engines Advisors, exiting entirely with an estimated $104K sold.
- 6 institutional investors held bioAffinity Technologies (BIAF) as of Q1 2023, up from 4 in Q4 2022.
- Funds reported $193K of bioAffinity Technologies stock for Q1 2023, up 45% quarter-over-quarter.
- 3 funds opened new bioAffinity Technologies positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest bioAffinity Technologies buyer in Q1 2023 was CAPTRUST Financial Advisors, an estimated $84.2K added.
- The largest bioAffinity Technologies seller in Q1 2023 was Financial Engines Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2023.